ACI Global Corp. Stock Analysis ACGJ

ACI Global Corp. develops pharmaceutical products. The company is headquartered in Greenwich, Connecticut and currently employs 3 full-time employees. The firm's drug candidates are proprietary synthetic and natural peptides (small proteins). Antecedents for these compounds occur in nature as part of the immune system of animals, insects and plants. Generally, the peptides bind to and kill harmful microorganisms and cancer cells. P113D, the Company's product candidate for cystic fibrosis, has been awarded Orphan Drug designation by the United States Food and Drug Administration (FDA). Demegen is also developing a novel, synthetic antimicrobial peptide in a rinse formulation for the treatment and prevention of oral candidiasis. The firm's peptide technology can also be used to prevent serious damage to crops caused by fungal and bacterial diseases.